- Home >
- Clinicals Trials >
- IROCAS - PRODIGE 52
IROCAS - PRODIGE 52
A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting
- Open at Saint-Cloud since : 15/11/2017
- Target : Adult
- Phase : Phase III
Trial description
The trial is a phase III, multicenter, open-labeled randomized trial comparing the association 5-fluorouracil, folinic acid, irinotecan and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, 5FU (mFOLFOX 6) chemotherapy protocols in patients with high-risk stage III colon cancer in the adjuvant setting.
Url of the trial